NCT01868009 - DISKUS vs. ELLIPTA Device Preference Study in Chronic Obstructive Pulmonary Disease (COPD) | Biotech Hunter

Enrollment

287

Participants

Timeline

Start Date

May 31, 2013

Primary Completion Date

July 31, 2013

Study Completion Date

July 31, 2013

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

DEVICE

ELLIPTA

Novel dry powder inhaler (placebo) with 30 doses (2 strips with 30 blisters per strip)

DEVICE

DISKUS

Multidose dry powder inhaler (placebo) containing a foil strip worth 60 blisters (1 strip with 60 blisters per strip)

Trial Locations (17)

23225

GSK Investigational Site, Richmond

28078

GSK Investigational Site, Huntersville

28207

GSK Investigational Site, Charlotte

29303

GSK Investigational Site, Spartanburg

29615

GSK Investigational Site, Greenville

29640

GSK Investigational Site, Easley

29678

GSK Investigational Site, Seneca

32825

GSK Investigational Site, Orlando

34748

GSK Investigational Site, Leesburg

35501

GSK Investigational Site, Jasper

70503

GSK Investigational Site, Lafayette

78229

GSK Investigational Site, San Antonio

92506

GSK Investigational Site, Riverside

97504

GSK Investigational Site, Medford

99204

GSK Investigational Site, Spokane

33765-2616

GSK Investigational Site, Clearwater

29406-7108

GSK Investigational Site, Charleston